Outcomes after asystole events occurring during wearable defibrillator-cardioverter use

Table 1 Patient demographics at the start of wearable cardioverter defibrillator use

Parameter	All (n = 257)	Not serious (n = 56)	Serious (n = 201)
Age, yr (median, range)	69 (25-90)	69 (25-82)	69 (39-90)
Sex
Male (%)	191 (74.3)	41 (73.2)	150 (74.6)
Female	65 (25.3)	15 (26.8)	50 (24.9)
NA	1 (0.4)	0 (0)	1 (0.5)
LVEF % (median, range) (n = 241 reported)	25 (10-65)	25 (10-65)	27.5 (10-60)
Primary indication, n (%)
MI/NICM	198 (77.0)	43 (76.8)	155 (77.1)
ICD Explant	22 (8.6)	6 (10.7)	16 (8.0)
VT/SCA	35 (13.6)	7 (12.5)	28 (13.9)
Genetic risk	1 (0.4)	0 (0)	1 (0.5)
NA	1 (0.4)	0 (0)	1 (0.5)
History of diabetes mellitus
Yes	128 (49.8)	18 (32.1)	110 (54.7)c
No	111 (43.2)	38 (67.9)	73 (36.3)
NA	18 (7.0)	0 (0)	18 (9.0)
History of ESRD/HD
Yes	34 (13.2)	5 (8.9)	29 (14.4)
No	204 (79.4)	51 (9.1)	153 (76.1)
NA	19 (7.4)	0 (0)	19 (9.5)
History of arrhythmias1	237	54	183
Patients reported
Any arrhythmia listed below	169 (71.3)	41 (75.9)	128 (69.9)
Sustained VT/VF	68 (28.7)	19 (35.2)	49 (26.8)
Bundle branch block	49 (20.7)	18 (33.3)b	31 (16.9)
AFib/Aflutter/SVT/AT	98 (41.4)	23 (42.6)	75 (41.0)
Bradycardia/Heart Block/PEA	31 (13.1)	6 (11.1)	25 (13.7)

¹Percentages were calculated based on patients with information.

^bP < 0.05 as no serious group compared to serious group using Fisher’s exact test, P-value are calculated based on patients with information;

^cP < 0.001 as no serious group compared to non-serious group using Fisher’s exact test. AFib: Atrial fibrillation; Aflutter: Atrial flutter; SVT: Supraventricular tachycardia; AT: Atrial tachycardia; PEA: Pulseless electrical activity; NA: Not reported.